Visualization of Endolymphatic Hydrops in Ménière’s Disease after Single-dose Intravenous Gadolinium-based Contrast Medium: Timing of Optimal Enhancement

Shinji NAGANAWA¹*, Masahiro YAMAZAKI¹, Hisashi KAWAI¹, Kiminori BOKURA¹, Michihiko SONE², and Tsutomu NAKASHIMA²

Departments of ¹Radiology and ²Otorhinolaryngology, Nagoya University Graduate School of Medicine
65 Tsurumai-cho, Showa-ku, Nagoya 466–8550, Japan
(Received July 28, 2011; Accepted August 31, 2011)

Purpose: Visualization of endolymphatic hydrops (EH) in patients with Ménière’s disease (MD) is now possible by heavily T₂-weighted 3-dimensional fluid-attenuated inversion recovery (hT₂W-3D-FLAIR) obtained 4 hours after intravenous (IV) administration of single dose gadolinium-based contrast medium (GBCM). Although maximum enhancement has been reported 4 hours after contrast administration in healthy volunteers, the timing of optimal enhancement in patients with MD is not reported. We investigated if that optimal timing is earlier or later than 4 hours.

Materials and Methods: We evaluated 10 consecutive patients with suspected MD whom we randomly divided into 2 groups. We obtained hT₂W-3D-FLAIR before GBCM administration and 10 min, 3.5 hours, and 4 hours after GBCM administration in Group A and before and 10 min, 4 hours, and 4.5 hours after GBCM administration in Group B. We compared signal intensity ratio (SIR) values of the perilymph and pons between 3.5 and 4 hours in Group A and between 4 and 4.5 hours in Group B and evaluated grades of EH at 3.5 and 4 hours in Group A and at 4 and 4.5 hours in Group B.

Results: SIR values did not differ significantly between 3.5 and 4 hours in Group A and between 4 and 4.5 hours in Group B. However, SIR values at 4 hours were significantly higher in Group A than Group B. Grades of EH agreed between 3.5 and 4 hours in Group A and between 4 and 4.5 hours in Group B.

Conclusion: The optimal timing of contrast enhancement in patients with suspected MD remains unclear, but evaluation of EH may be possible from 3.5 to 4.5 hours after contrast administration.

Keywords: intravenous, magnetic resonance imaging, Ménière’s disease, 3D imaging

Introduction

Visualization of endolymphatic hydrops (EH) in patients with Ménière’s disease was made possible first by 3-dimensional fluid-attenuated inversion recovery (3D-FLAIR) imaging obtained 24 hours after intratympanic (IT) administration of gadolinium-based contrast medium (GBCM); then by 3D-FLAIR imaging 4 hours after intravenous (IV) injection of double-dose GBCM; and recently, following the development of heavily T₂-weighted 3D-FLAIR (hT₂W-3D-FLAIR) imaging, after IV injection of single-dose GBCM. These 3 methods utilize the preferential enhancement of the perilymph for separate visualization of the endo- and perilymph. A scale for grading EH on MR images has been proposed using 3D-FLAIR and 3D-real inversion recovery sequences obtained after IT administration of GBCM. Grading on MR images has been correlated with results of various clinical tests, such as evaluations of vestibular-evoked myogenic potential and low frequency hearing, and the degree of EH has been associated with progressive loss of auditory and sacculus function in patients with Ménière’s disease. During follow-up of treatment response in these patients, the degree of endolymphatic hydrops correlated with hearing level. No study has directly compared EH grades on images obtained following IT and IV administration of...
Materials and Methods

The medical ethics committee of our institution approved this study, and we obtained informed consent from all patients. We evaluated 10 consecutive patients with suspected Ménière’s disease (6 men, 4 women, aged 27 to 67 years). Bilateral disease was suspected in one patient; “cochlear-type” Ménière’s disease, in which there is low-tone or fluctuating hearing loss, was suspected in 2 patients (but they did not demonstrate rotating vertigo) and unilateral disease was suspected in the other 7 patients. Experienced otolaryngologists made the clinical diagnosis based on the 2008 Japanese guideline for diagnosing Ménière’s disease.

The patients underwent scanning before and after single-dose (0.2 mL/kg or 0.1 mmol/kg body weight) intravenous administration of gadolinium-diethylenetriamine pentaacetic acid-bis (methylamide) (Gd-DTPA-BMA; Omniscan, Daiichi-Sankyo Co., Ltd., Tokyo, Japan) to evaluate the degree of endolymphatic hydrops. The estimated glomerular filtration rate (eGFR) in all patients exceeded 60 mL/min/1.73 m². We calculated each GFR using an equation reported by the Japanese Society of Nephrology for estimating GFR (eGFR) in Japanese patients based on serum creatinine level (Cr): eGFR (mL/min/1.73 m²) = 194 × Cr⁻¹.094 × Age⁻0.287 (if female, × 0.739). We divided the 10 patients randomly into 2 groups of 5 patients each.

We performed all MR imaging using a 3-tesla unit (Verio, Siemens, Erlangen, Germany) with a 32-channel array head coil. For anatomical reference of the total fluid space of the labyrinth and cistern, we obtained heavily T₂-weighted fast recovery 3D turbo-spin-echo images: repetition time (TR), 1500 ms; echo time (TE), 130 ms; 180° flip angle (constant throughout echo train) for the conventional turbo-spin-echo refocusing echo train; echo train length, 23 with restore magnetization pulse (fast recovery pulse); matrix size, 384 × 384; 12 axial slices of 2.0-mm thickness covering the labyrinth; field of view (FOV), 16 × 16 cm; generalized autocalibrating partially parallel acquisition (GRAPPA) parallel imaging technique; acceleration factor, 2; number of excitations (NEX), one; and scan time, 2.7 min.

Scan parameters of hT₂W-3D-FLAIR were: TR, 9000 ms; TE, 546 ms; TI, 2350 ms; frequency-selective fat-suppression pre-pulse initial refocusing flip angle, 180°, rapidly decreased to constant 120° flip angle for the turbo-spin-echo refocusing echo train; echo train length, 107; matrix size, 214 × 256; 112 axial slices of 0.8-mm thickness covering the labyrinth; FOV, 15 × 18 cm; GRAPPA technique; acceleration factor, 2; NEX, 2; and scan time, 5.7 min.

All patients underwent MR cisternography and hT₂W-3D-FLAIR prior to single-dose IV administration of GBCM (first scan) and a second hT₂W-3D-FLAIR scan 10 min after contrast administration, then came out of the magnet to rest. The 5 members of Group A then underwent hT₂W-3D-FLAIR scanning at 3.5 (third scan) and 4 hours (fourth scan) after contrast administration, and members of Group B, at 4 (third scan) and 4.5 hours (fourth scan) after GBCM administration.

On the PACS viewer (RapidEye, Toshiba, Tokyo, Japan), a radiologist with 22 years’ experience drew regions of interest (ROI) in the cochlear...
and vestibular perilymph, vestibular endolymph, and cerebrospinal fluid (CSF) space in the fundus of the internal auditory canal (IAC) on the \( \text{hT}_2 \text{W-3D-FLAIR} \) images obtained 3.5, 4, and 4.5 hours after IV administration of GBCM. The ROIs were drawn as circles of: 0.7-mm diameter in the scala tympani of the cochlear basal turn based on reference to MR cisternography for the cochlear perilymph; one-mm diameter in the anterior superior part of the vestibular perilymph area for the vestibular perilymph; one-mm diameter in the utricle, that is, the area of low signal in the upper part of the vestibule, for the vestibular endolymph; and one-mm in the CSF space in the area between the cochlear nerve and inferior vestibular nerve based on reference to MR cisternography for the CSF space in the fundus of the IAC. Figure 1 shows an example of the ROI placement. We normalized signal intensity values of the ROIs by dividing them by the signal intensity value of the pons and defined this normalized value as the signal intensity ratio (SIR). We measured the signal intensity of the pons

---

**Fig. 1.** Example of region of interest (ROI) placement. A 48-year-old man with right Ménière’s disease in Group A. (a) Magnetic resonance (MR) cisternographic image at cochlear level. (b) Corresponding heavily \( T_2 \)-weighted 3-dimensional fluid-attenuated inversion recovery (\( \text{hT}_2 \text{W-3D-FLAIR} \)) image at the cochlear level obtained 3.5 hours after intravenous (IV) injection of gadolinium-based contrast medium (GBCM). Circular ROI in the scala tympani of the cochlear basal turn. (c) and (d), \( \text{hT}_2 \text{W-3D-FLAIR} \) images obtained 3.5 hours after IV administration of GBCM. Circular ROI in the vestibular endolymph (c) and vestibular perilymph (d). (e) MR cisternographic image at the level of the cochlear nerve. (f) Circular ROI for the cerebrospinal fluid in the internal auditory canal on \( \text{hT}_2 \text{W-3D-FLAIR} \) image obtained 3.5 hours after IV administration of GBCM.
in a circular ROI of 5-mm diameter drawn in the center of the pons.

We compared the average SIR values for each ROI of all 10 ears (right and left side in 5 patients) between 3.5 and 4 hours for Group A and between 4 and 4.5 hours for Group B and performed the same comparison for only those ears with endolymphatic hydrops in either the cochlea or vestibule, excluding nondiseased ears. We analyzed statistics using Student's t-test.

Two neuroradiologists with 22 and 12 years' experience independently reviewed the images for qualitative analysis. They evaluated all precontrast \( T_2 \)-weighted 3D-FLAIR images and those obtained at 10 min, 3.5 and 4 hours, or 4 and 4.5 hours after IV administration of GBCM for presence or absence of high signal equivalent to that of vestibulocochlear nerve bundle in labyrinthine fluid and CSF in the internal auditory canal. The 2 reviewers resolved any discrepancy by consensus after discussion. They also graded the degree of EH separately for the cochlea and vestibule as none, mild, or significant according to previously reported criteria for the cochlea and vestibule as none, mild, or significant according to previously reported criteria for the cochlea and vestibule. They also graded the degree of EH separately for the cochlea and vestibule as none, mild, or significant according to previously reported criteria for the cochlea and vestibule. They also graded the degree of EH separately for the cochlea and vestibule as none, mild, or significant according to previously reported criteria for the cochlea and vestibule.

The SIR values of the cochlear and vestibular perilymph, vestibular endolymph, and CSF in the IAC fundus were significantly higher in Group A than B at 4 hours \((P<0.05)\) (Table 3). The SIR values of the cochlear and vestibular perilymph were significantly higher in Group A than B at 4 hours \((P<0.05)\) (Table 3). The SIR values of the cochlear and vestibular perilymph were significantly higher in Group A than B at 4 hours \((P<0.05)\). No significant difference was found for the vestibular endolymph and CSF in the IAC fundus \((P>0.05)\). When limited to ears with endolymphatic hydrops in either the cochlea and/or vestibule and excluding ears without EH, the SIR values of the cochlear and vestibular perilymph were significantly higher in Group A than B at 4 hours \((P<0.05)\). No significant difference was found for the vestibular endolymph and CSF in the IAC fundus \((P>0.05)\).

Although the difference was not significant, the SIR values of the cochlear and vestibular perilymph...
Fig. 2. A 48-year-old man with right Ménière’s disease in Group A, same patient as Fig. 1. (a) Pre-contrast-enhanced heavily T2-weighted 3-dimensional fluid-attenuated inversion recovery (hT2W-3D-FLAIR) image at the cochlear nerve level. (b) Image obtained 10 min after intravenous (IV) injection of gadolinium-based contrast medium (GBCM). (c) Image obtained 3.5 hours after IV administration of GBCM. (d) Image obtained 4 hours after IV administration of GBCM. (e) Corresponding MR cisternographic image. Note that there is no high signal lymph fluid in the labyrinth and cerebrospinal fluid (CSF) in the internal auditory canal (IAC) equivalent to that of vestibulocochlear nerve (VIII) on (a) and (b). On the other hand, high signal is seen in the labyrinth and IAC on (c) and (d). On these slices, mild vestibular endolymphatic hydrops (EH) can be appreciated as low signal (arrow on [c] and [d]) surrounded by enhanced perilymph.

Table 4 shows the results of endolymphatic hydrops grading. One patient demonstrated no EH in either the cochlea or vestibule on either side. The other 9 patients had either cochlear or vestibular EH in at least one ear. Grading of endolymphatic hydrops on images obtained at 3.5 and 4 hours and at 4 and 4.5 hours after contrast administration agreed completely in both 2 observers. However, the observer with shorter experience underestimated significant EH as mild in one cochlea in images obtained at 3.5 and 4 hours after IV administration of GBCM in Group A (weighted kappa value, 0.941) and in 2 cochleas in images obtained at 4 and 4.5 hours after GBCM administration in Group B (weighted kappa value, 0.889). The 2 observers agreed regarding EH grading of the vestibule.

EH grading of the cochlea did not differ significantly between Groups A and B, but vestibular grades were significantly higher in Group A than B (P<0.05).

Discussion

The hT2W-3D-FLAIR technique has been reported to be more sensitive than conventional 3D-FLAIR in detecting low concentrations of GBCM in fluid. Evaluation of endolymphatic hydrops in the clinical setting is now feasible using hT2W-3D-FLAIR and single-dose GBCM administered intravenously.5 EH grades on images obtained after IV administration of GBCM correlated with low frequency hearing level.8 However, the degree of perilymph enhancement after IV administration of GBCM does not correlate with hearing level in patients with Ménière’s disease.11 More widespread use of this method in the clinic requires knowledge of the
Fig. 3. A 74-year-old woman with right Ménière’s disease in Group B. (a) Pre-contrast-enhanced heavily T2-weighted 3-dimensional fluid-attenuated inversion recovery (hT2W-3D-FLAIR) image at the cochlear nerve level. (b) Image obtained 10 min after intravenous (IV) injection of gadolinium-based contrast medium (GBCM). (c) Image obtained 4 hours after IV administration of GBCM. (d) Image obtained 4.5 hours after IV administration of GBCM. (e) Corresponding magnetic resonance (MR) cisternographic image. Note that there is no high signal lymph fluid in the labyrinth and cerebrospinal fluid (CSF) in the internal auditory canal (IAC) equivalent to that of vestibulocochlear nerve (VIII) on (a) and (b). On the other hand, high signal is seen in the labyrinth and IAC on (c) and (d). On these slices, significant cochlear endolymphatic hydrops (EH) can be appreciated as low signal (arrow on [c] and [d]).

Table 2. Comparison of signal intensity ratio in all ears

|                | Group A (10 ears) | Group B (10 ears) |
|----------------|-------------------|-------------------|
|                | 3.5 hours average | 4 hours average   |
|                | SD                | SD                |
| cochlear perilymph | 11.5 3.3          | 12.2 4.3          |
| vestibular perilymph | 12.1 3.0          | 12.7 3.1          |
| CSF in IAC      | 12.4 5.0          | 13.1 5.9          |
| vestibular endolymph | 0.6 0.5           | 0.4 0.5           |
|                | 3.5 hours average | 4 hours average   |
|                | SD                | SD                |
| cochlear perilymph | 7.9 1.8           | 8.3 0.8           |
| vestibular perilymph | 9.0 2.9           | 9.1 2.4           |
| CSF in IAC      | 8.9 3.7           | 9.3 4.4           |
| vestibular endolymph | 0.7 0.7           | 0.5 0.6           |
| CSF in IAC, cerebrospinal fluid in internal auditory canal; n.s., not significant; SD, standard deviation

Table 3. Comparison of signal intensity ratio in ears with endolymphatic hydrops

|                | Group A (9 ears) | Group B (7 ears) |
|----------------|-----------------|-----------------|
|                | 3.5 hours average | 4 hours average   |
|                | SD                | SD                |
| cochlear perilymph | 11.8 3.4          | 12.5 4.4          |
| vestibular perilymph | 12.3 3.1          | 12.8 3.3          |
| CSF in IAC      | 12.6 5.2          | 13.5 6.1          |
| vestibular endolymph | 0.7 0.5           | 0.5 0.5           |
|                | 3.5 hours average | 4 hours average   |
|                | SD                | SD                |
| cochlear perilymph | 7.9 2.1           | 8.2 1.0           |
| vestibular perilymph | 9.3 3.2           | 9.5 2.5           |
| CSF in IAC      | 10.1 2.8          | 11.0 3.8          |
| vestibular endolymph | 0.7 0.6           | 0.5 0.6           |
| CSF in IAC, cerebrospinal fluid in internal auditory canal; n.s., not significant; SD, standard deviation

Magnetic Resonance in Medical Sciences
Table 4. Summary of patients and grading of endolymphatic hydrops

| Group A (3.5 versus 4 hours) | age/disease | gender | side | cochlea | vestibule |
|-----------------------------|-------------|--------|------|---------|-----------|
|                             | 34          | male   | right| 2       | 2         |
|                             | right Ménière's disease | 67 | male | right | 2 | 2 |
|                             | 60          | male   | left | 0       | 0         |
|                             | right Ménière's disease | 48 | male | right | 2 | 1 |
|                             | 50          | male   | left | 0       | 2         |

| Group B (4 versus 4.5 hours) | age/disease | gender | side | cochlea | vestibule |
|-----------------------------|-------------|--------|------|---------|-----------|
|                             | 27          | female | right| 0       | 1         |
|                             | left Ménière's disease | 74 | female | left | 2 | 0 |
|                             | right Ménière's disease | 66 | female | left | 0 | 0 |
|                             | bilateral Ménière's disease | 31 | female | right | 2 | 0 |
|                             | bilateral cochlear type Ménier's disease | 33 | male | right | 0 | 0 |
|                             | right Ménier's disease | 50 | male | left | 0 | 1 |

Grade of endolymphatic hydrops: 0, none; 1, mild; 2, significant

optimal timing after IV administration of GBCM for evaluating endolymphatic grade in patients with Ménier's disease.

Our study results showed no high signal in the labyrinthine fluid and CSF in the internal auditory canal equivalent to that of vestibulocochlear nerve bundle on hT2W-3D-FLAIR images obtained before and 10 min after IV administration of GBCM. However, high signal was observed in the labyrinth and IAC in all ears on hT2W-3D-FLAIR images obtained 3.5 and 4 hours or 4 and 4.5 hours after IV administration of GBCM and can be concluded to represent contrast enhancement resulting from the slow permeation of GBCM.

In the present study, SIR values did not differ significantly between hT2W-3D-FLAIR images obtained 3.5 hours and 4 hours after IV administration of GBCM in Group A and 4 and 4.5 hours after GBCM administration in Group B. However, SIR values of the cochlear vestibular perilymph differed significantly at 4 hours between Groups A and B. Therefore, we cannot conclude that there is no significant difference between SIR values at 3.5 hours in Group A and 4.5 hours in Group B.

Though the differences were not significant, the average SIR values of the cochlear and vestibular perilymph were larger on the fourth scan than the third in both groups. This tendency in a small number of patients suggests that optimal timing might be later than 4 hours.

Grading of endolymphatic hydrops agreed between 3.5 and 4 hours in Group A and between 4 and 4.5 hours in Group B. Furthermore, weighted kappa values for cochlear grading between the 2 observers were as high as 0.941 for Group A and 0.889 for Group B. Vestibular grading by the 2 observers agreed completely. Therefore, EH grading may be feasible between 3.5 and 4.5 hours after contrast administration, though we could not conclude the optimal timing of enhancement within this wide range in patients with Ménier's disease. Further study comparing SIR values at 3 time points, such as at 3, 4, and 5 hours, in the same subjects might clarify the optimal timing of enhancement.

Our study is limited by the small number of patients and our inclusion of ears with both mild and significant endolymphatic hydrops as ears with
EH. However, because we cannot know if a patient has endolymphatic hydrops in the clinical setting before MR examination, it is practical to target scan timing for ears without EH as well as ears with mild and significant EH. In the present study, we used the results of endolymphatic hydrops grading to separate ears with and without EH. Even excluding ears without EH, our comparison showed no significant difference between SIR values on the third (3.5 hours in Group A; 4 hours in Group B) and fourth scan (4 hours in Group A; 4.5 hours in Group B). These findings resemble those of comparison between the third and fourth scans for all ears.

Another limitation is the dissimilarity of Groups A and B. The degree of vestibular endolymphatic hydrops differed between the 2 groups, and SIR values differed significantly at 4 hours between them. As a result, we could not determine whether the optimal timing of enhancement is earlier or later than 4 hours. However, at least our results indicate that a clinically convenient timing for grading endolymphatic hydrops might be feasible between 3.5 and 4.5 hours after IV administration of GBCM.

In previous study, 14 ears with Ménière’s disease showed 36% more intense enhancement than 10 asymptomatic contralateral ears of patients with unilateral Ménière’s disease, and hydrops grade correlated significantly with contrast effect.8 In the present study, significantly higher grades of vestibular endolymphatic hydrops in Group A than B may be responsible for the significantly higher SIR values of the perilymph at 4 hours in Group A than B. In some pathological states, such as sudden deafness,12 labyrinthine fistula caused by cholesteroloma,13 and Ramsay-Hunt syndrome,14 prompt contrast enhancement has been observed in the labyrinth on images obtained 10 min after IV administration of GBCM. Maximum perilymph enhancement might be observed much earlier than 4 hours in these pathological states. In the present study, no ear showed contrast enhancement in the labyrinth on images obtained 10 min after IV administration of GBCM, which suggests that ears with Ménière’s disease do not have the severely increased permeability of the blood-perilymph barrier as do the pathological states described above.

In conclusion, we could not determine the optimal timing of enhancement to visualize endolymphatic hydrops in patients with Ménière’s disease but believe that its grading may be feasible 3.5 to 4.5 hours after IV administration of GBCM. Although there was no significant difference, the SIR values of the fourth scan were larger than those of the third in both Group A and B. Further study comparing the SIR values on images obtained at 3 time points, such as 3, 4, and 5 hours, after IV administration of GBCM in patients with Ménière’s disease may be necessary to determine whether the optimal timing is earlier or later than 4 hours.

References

1. Nakashima T, Naganawa S, Sugiura M, et al. Visualization of endolymphatic hydrops in patients with Ménière’s disease. Laryngoscope 2007; 117: 415–420.
2. Nakashima T, Naganawa S, Teranishi M, et al. Endolymphatic hydrops revealed by intravenous gadolinium injection in patients with Ménière’s disease. Acta Otolaryngol 2010; 130:338–343.
3. Naganawa S, Yamazaki M, Kawai H, Tokumara K, Sone M, Nakashima T. Visualization of endolymphatic hydrops in Ménière’s disease with single-dose intravenous gadolinium-based contrast medium using heavily T2-weighted 3D-FLAIR. Magn Reson Med Sci 2010; 9:237–242.
4. Nakashima T, Naganawa S, Pyykko I, et al. Grading of endolymphatic hydrops using magnetic resonance imaging. Acta Otolaryngol Suppl 2009; (560):5–8.
5. Katayama N, Yamamoto M, Teranishi M, et al. Relationship between endolymphatic hydrops and vestibular-evoked myogenic potential. Acta Otolaryngol 2010; 130:917–923.
6. Gürkov R, Flatz W, Louza J, Strupp M, Krause E. In vivo visualization of endolymphatic hydrops in patients with Ménière’s disease: correlation with audiovestibular function. Eur Arch Otorhinolaryngol 2011; 268:1743–1748.
7. Sone M, Naganawa S, Teranishi M, Nakata S, Katayama N, Nakashima T. Changes in endolymphatic hydrops in a patient with Ménière’s disease observed using magnetic resonance imaging. Auris Nasus Larynx 2010; 37:220–222.
8. Tagaya M, Yamazaki M, Teranishi M, et al. Endolymphatic hydrops and blood-labyrinth barrier in Ménière’s disease. Acta Otolaryngol 2011; 131: 474–479.
9. Naganawa S, Komada T, Fukatsu H, Ishigaki T, Takizawa O. Observation of contrast enhancement in the cochlear fluid space of healthy subjects using a 3D-FLAIR sequence at 3 Tesla. Eur Radiol 2006; 16:733–737.
10. Naganawa S, Kawai H, Sone M, Nakashima T. Increased sensitivity to low concentration gadolinium contrast by optimized heavily T2-weighted 3D-FLAIR to visualize endolymphatic space. Magn Reson Med Sci 2010; 9:73–80.
11. Suzuki H, Teranishi M, Sone M, Yamazaki M, Naganawa S, Nakashima T. Contrast enhancement of the inner ear after intravenous administra-
tion of a standard or double dose of gadolinium contrast agents. Acta Otolaryngol 2011; 131:1025–1031.

12. Sugiura M, Naganawa S, Teranishi M, Nakashima T. Three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging findings in patients with sudden sensorineural hearing loss. Laryngoscope 2006; 116:1451–1454.

13. Sone M, Mizuno T, Sugiura M, Naganawa S, Nakashima T. Three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging investigation of inner ear disturbances in cases of middle ear cholesteatoma with labyrinthine fistula. Otol Neurotol 2007; 28:1029–1033.

14. Nakata S, Mizuno T, Naganawa S, et al. 3D-FLAIR MRI in facial nerve paralysis with and without audio-vestibular disorder. Acta Otolaryngol 2010; 130:632–636.